WaveMan
WaveMan · Company
MDCX · Medicus Pharma Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

MDCX Medicus Pharma (MDCX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001997296
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
16
13F, latest reported quarter

What the filings say about MDCX

Activist stakes (13D), 180 days
1 filing
Largest: 5.3% of the class

Medicus Pharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Medicus Pharma Ltd. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Melani Kenneth R.
SELL
2025-05-21 SECtraded 2025-05-20
75,000
$579.0K
-64.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 2.3% of the 3,248,741 shares held after it.
  • No other insider sold within 30 days.
  • 16 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Melani Kenneth R. sold about $579.0K of MDCX on May 20, 2025, the largest insider sale at the company on our record; 16 funds added in the latest 13F quarter.
1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
16 funds bought in last quarter
below 72% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.2% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 90% of Pharma & Biotech
The situation: each line is one rule over one dataset
BOKHARI, RAZA disclosed a 5%+ stake (5.3%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MDCX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+3.3%12M
-93%+22%+137%+252%2025-102025-122026-022026-042026-062026-082026-10 2026-09-14 · BOKHARI, RAZA filed a 5%+ stake (5.3%)2026-09-14 · RBx Capital, LP filed a 5%+ stake (0.9%)
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MDCX: institutional holders (13F)

13F holdings, latest reported quarter
Interchange Capital Partners, LLC
1,586,871 sh
$718.4K
JANE STREET GROUP, LLC
333,673 sh
$148.9K
XTX Topco Ltd
243,362 sh
$108.6K
Sterling Investment Advisors, Ltd.
100,000 sh
$44.6K
ARMISTICE CAPITAL, LLC
60,600 sh
$39.4K

Congress trades in MDCX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
BOKHARI, RAZA
Activist 13D · 2026-09-14
5.3%
RBx Capital, LP
Activist 13D · 2026-09-14
0.9%

MDCX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

MDCX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Nasdaq Composite Index Fund
$1.4K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 16 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MDCX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-12.51x
TTM operating cash flow over current debt only, 2026-03-31
Return on equity
-7,631%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-290.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$145.8M
market value at close 2026-10-26 on 2026-08-10 shares, plus current debt only, 2026-03-31, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Operating income-$34.4M-$11.2M-$4.7M
Net income-$47.3M-$11.2M-$5.3M
EPS (diluted)-2.74-1.16-1.53
Operating cash flow-$22.8M-$10.2M-$4.2M
Cash$8.7M$4.2M$1.7M
SEC XBRL, fiscal years, as known on 2026-10-28

MDCX Stock Sonar score 4/7 axes

Find similar shapesCompare

MDCX ranks highest on risk and compliance (62nd percentile) and institutional and government (28th), and lowest on profitability (4th), among Pharma & Biotech peers.

Profitability
4
Inputs
  • Return on equity-7631% · 1 pct, sector of 545
  • Return on assets-290.2% · 7 pct, sector of 691
  • Return on invested capitalthe filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Return on capital employedthe filed year and its quarters do not reconcile, so the trailing figure is withheld
Financial health
22
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-12.51x · 22 pct, sector of 371
Institutional and government
28
Inputs
  • Funds adding, latest quarter16 · 28 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
62
Inputs
  • Short interest, % of float+4.2% · 62 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Growth, Insider conviction, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MDCX filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 5.3% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies